Form 4: Ironwood Pharmaceuticals Director Stock Transaction

Catherine Moukheibir, a Director at Ironwood Pharmaceuticals, reported a transaction involving Class A Common Stock on June 16, 2026.

Summary

• Catherine Moukheibir, a Director at Ironwood Pharmaceuticals, Inc., acquired 63,481 shares of Class A Common Stock on June 16, 2026.
• The acquisition was made under a restricted stock grant, effective January 1, 2024, as part of the Non-employee Director Compensation Policy.
• These restricted shares vest in full on the day before the next annual stockholders meeting.
• Following the transaction, Moukheibir beneficially owns 181,425 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard compensation-related stock grant to a director and does not provide new financial or strategic information.

Positives

• Director Catherine Moukheibir received a significant grant of restricted stock, indicating continued alignment with shareholder interests.
• The restricted stock vests fully, providing a clear incentive for long-term commitment to the company.
• The transaction details are transparently reported, adhering to SEC disclosure requirements.

Negatives

• The filing does not detail the specific market value or cost basis of the restricted stock grant at the time of acquisition, only that it was acquired at a price of $0.
• The filing is a Form 4, which reports changes in beneficial ownership and does not provide operational or financial performance updates.

Risks

• The vesting schedule of the restricted stock is tied to the annual meeting of stockholders, meaning any significant corporate events prior to that could impact the director's continued holding of the shares.
• As a Form 4 filing, it does not contain forward-looking statements or explicit risk factors related to the company's business operations.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance. The vesting of the restricted stock is contingent on the date of the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into director and officer holdings. This specific filing indicates a routine compensation event for a director at Ironwood Pharmaceuticals, rather than a strategic business update.

Corporate Governance

Stakeholder Impact

• Shareholders: The transaction reflects a standard compensation practice for directors, reinforcing their commitment to the company's long-term success.
• Employees: No direct impact on employees is indicated by this filing.
• Management: The filing is a routine disclosure for a director's compensation.

Next Steps

• The restricted stock will vest in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.
• Further transactions by Catherine Moukheibir will be reported on subsequent Form 4 filings.

Key Dates

Keywords

Form 4, SEC Filing, Ironwood Pharmaceuticals, Catherine Moukheibir, Director, Restricted Stock, Stock Transaction, Beneficial Ownership, Class A Common Stock